{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:50Z","timestamp":1793147990783,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1136\/ard.2007.087130","type":"journal-article","created":{"date-parts":[[2008,5,9]],"date-time":"2008-05-09T01:11:39Z","timestamp":1210295499000},"page":"552-557","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis"],"prefix":"10.1016","volume":"68","author":[{"given":"P","family":"Tynj\u00e4l\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"V\u00e4h\u00e4salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Honkanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lahdenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.2007.087130_bib1","first-page":"271","article-title":"Toward an understanding of the long-term outcome of juvenile idiopathic arthritis.","volume":"22","author":"Ravelli","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib2","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate.","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.087130_bib3","first-page":"599","article-title":"Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG\/PRINTO phase IV post marketing surveillance study.","volume":"24","author":"Ruperto","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/112067210701700509","article-title":"Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication.","volume":"17","author":"Heiligenhaus","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1136\/ard.2007.087130_bib5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2007.087130_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.087130_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1136\/ard.62.3.245","article-title":"Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.","volume":"62","author":"Lahdenne","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.087130_bib8","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.087130_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1136\/ard.2005.044404","article-title":"Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study.","volume":"65","author":"Weinblatt","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.087130_bib10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/ard.2006.058248","article-title":"Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.","volume":"66","author":"Tynjala","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.087130_bib11","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jpeds.2006.04.058","article-title":"Adalimumab therapy for childhood uveitis.","volume":"149","author":"Vazquez-Cobian","year":"2006","journal-title":"J Pediatr"},{"key":"10.1136\/ard.2007.087130_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood.","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Opthalmol"},{"key":"10.1136\/ard.2007.087130_bib13","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis.","volume":"47","author":"Tynj\u00e4l\u00e4","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2007.087130_bib15","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.087130_bib16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis.","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2007.087130_bib17","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1136\/ard.2007.087130_bib19","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.087130_bib21","first-page":"935","article-title":"Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.","volume":"32","author":"Kimura","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib22","first-page":"2055","article-title":"Prolonged efficacy of etanercept in refractory enthesitis-related arthritis.","volume":"31","author":"Henrickson","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib23","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/art.21121","article-title":"Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.","volume":"52","author":"Tse","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2007.087130_bib24","first-page":"386","article-title":"Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years.","volume":"30","author":"Flato","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib25","first-page":"295","article-title":"The natural history of juvenile chronic arthritis: a population based cohort study. I. Onset and disease process.","volume":"22","author":"Gare","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2007.087130_bib26","first-page":"25","article-title":"Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt Study.","volume":"80","author":"Allaart","year":"2007","journal-title":"J Rheumatol Suppl"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724425624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724425624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2007.087130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:52:14Z","timestamp":1737359534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724425624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S0003496724425624"],"URL":"https:\/\/doi.org\/10.1136\/ard.2007.087130","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2007.087130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 2009 Published by Elsevier Inc. Publishing Group and European League Against Rheumatism. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}